183.09
price down icon1.42%   -2.63
after-market アフターアワーズ: 183.99 0.90 +0.49%
loading
前日終値:
$185.72
開ける:
$185.35
24時間の取引高:
4.78M
Relative Volume:
0.62
時価総額:
$323.41B
収益:
$57.37B
当期純損益:
$4.20B
株価収益率:
77.91
EPS:
2.35
ネットキャッシュフロー:
$15.39B
1週間 パフォーマンス:
+0.71%
1か月 パフォーマンス:
-4.81%
6か月 パフォーマンス:
+0.01%
1年 パフォーマンス:
+17.86%
1日の値動き範囲:
Value
$182.37
$186.10
1週間の範囲:
Value
$180.25
$186.10
52週間の値動き範囲:
Value
$153.58
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
名前
Abbvie Inc
Name
セクター
Healthcare (1171)
Name
電話
(847) 932-7900
Name
住所
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
職員
55,000
Name
Twitter
@abbvie
Name
次回の収益日
2025-04-25
Name
最新のSEC提出書
Name
ABBV's Discussions on Twitter

ABBV を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
183.09 321.13B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
719.39 650.81B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
152.43 368.56B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
111.87 222.75B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
68.60 303.04B 43.59B 15.04B 10.74B 3.3766

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-14 ダウングレード Citigroup Buy → Neutral
2025-04-22 開始されました Cantor Fitzgerald Overweight
2024-12-10 再開されました BofA Securities Neutral
2024-12-05 ダウングレード Daiwa Securities Outperform → Neutral
2024-11-22 アップグレード Leerink Partners Market Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-11-04 アップグレード Argus Hold → Buy
2024-10-17 開始されました Bernstein Mkt Perform
2024-06-05 アップグレード HSBC Securities Hold → Buy
2024-05-17 開始されました Cantor Fitzgerald Overweight
2024-01-29 アップグレード William Blair Mkt Perform → Outperform
2023-12-18 ダウングレード HSBC Securities Buy → Hold
2023-12-11 アップグレード Goldman Neutral → Buy
2023-11-09 開始されました Deutsche Bank Hold
2023-10-30 アップグレード Barclays Equal Weight → Overweight
2023-10-20 再開されました UBS Neutral
2023-09-29 開始されました Raymond James Outperform
2023-07-25 開始されました William Blair Mkt Perform
2023-07-14 開始されました HSBC Securities Buy
2023-04-05 ダウングレード Argus Buy → Hold
2023-03-01 開始されました Guggenheim Buy
2023-02-22 ダウングレード Wolfe Research Outperform → Peer Perform
2023-02-10 アップグレード SVB Securities Underperform → Market Perform
2022-11-18 開始されました Credit Suisse Outperform
2022-11-08 ダウングレード Societe Generale Buy → Hold
2022-08-01 ダウングレード Atlantic Equities Overweight → Neutral
2022-05-23 開始されました SVB Leerink Underperform
2022-05-06 ダウングレード Daiwa Securities Outperform → Neutral
2022-04-06 再開されました Morgan Stanley Overweight
2022-02-28 ダウングレード UBS Buy → Neutral
2022-02-03 繰り返されました BMO Capital Markets Outperform
2022-02-03 繰り返されました Barclays Equal Weight
2022-02-03 繰り返されました BofA Securities Neutral
2022-02-03 繰り返されました Goldman Neutral
2022-01-13 開始されました Redburn Buy
2022-01-12 繰り返されました BMO Capital Markets Outperform
2021-12-09 再開されました Wells Fargo Overweight
2021-11-23 アップグレード Societe Generale Hold → Buy
2021-07-27 再開されました Truist Buy
2021-04-07 再開されました RBC Capital Mkts Outperform
2020-11-10 再開されました Bernstein Outperform
2020-09-29 開始されました Berenberg Hold
2020-06-23 アップグレード Atlantic Equities Neutral → Overweight
2020-06-09 アップグレード Wolfe Research Peer Perform → Outperform
2020-06-02 アップグレード Argus Hold → Buy
2020-05-18 再開されました BofA/Merrill Neutral
2020-05-12 アップグレード JP Morgan Neutral → Overweight
2020-05-11 再開されました Morgan Stanley Overweight
2020-04-20 アップグレード RBC Capital Mkts Sector Perform → Outperform
2020-03-23 ダウングレード Societe Generale Buy → Hold
2020-02-27 開始されました Barclays Equal Weight
2020-02-06 開始されました Mizuho Buy
2020-01-07 開始されました RBC Capital Mkts Sector Perform
2019-12-26 繰り返されました Cowen Outperform
2019-09-26 アップグレード Citigroup Neutral → Buy
2019-08-20 アップグレード Piper Jaffray Neutral → Overweight
2019-06-27 アップグレード Wolfe Research Underperform → Peer Perform
2019-06-26 アップグレード SVB Leerink Mkt Perform → Outperform
2019-05-28 開始されました Goldman Neutral
2019-04-29 アップグレード BMO Capital Markets Underperform → Market Perform
すべてを表示

Abbvie Inc (ABBV) 最新ニュース

pulisher
04:51 AM

Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies - marketscreener.com

04:51 AM
pulisher
03:27 AM

CERE DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.

03:27 AM
pulisher
01:47 AM

AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers - Yahoo Finance

01:47 AM
pulisher
11:58 AM

Bearish Sentiment and Increased Put Activity for AbbVie (ABBV) | - GuruFocus

11:58 AM
pulisher
10:16 AM

Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies - BioSpace

10:16 AM
pulisher
10:14 AM

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - sharewise

10:14 AM
pulisher
09:44 AM

Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire

09:44 AM
pulisher
09:10 AM

AbbVie’s Allergan cuts over 200 staff after botched marketing campaign - PharmaLive

09:10 AM
pulisher
May 27, 2025

AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit - MSN

May 27, 2025
pulisher
May 27, 2025

AbbVie To Present Cancer Trial Data At Upcoming ASCO Event - Benzinga

May 27, 2025
pulisher
May 27, 2025

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio - Investing News Network

May 27, 2025
pulisher
May 27, 2025

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio | ABBV Stock News - GuruFocus

May 27, 2025
pulisher
May 26, 2025

Tissue Engineering Market Generated Opportunities, Future - openPR.com

May 26, 2025
pulisher
May 26, 2025

Prurigo Nodularis Market - GlobeNewswire Inc.

May 26, 2025
pulisher
May 26, 2025

AbbVie’s SWOT analysis: biopharma giant faces pipeline challenges amid stock growth - Investing.com

May 26, 2025
pulisher
May 26, 2025

Precision immunology Market Growth in Future Scope 2025-2032 | - openPR.com

May 26, 2025
pulisher
May 26, 2025

Immunomodulatory Drugs Market in 2025 Detailed Study Analysis | - openPR.com

May 26, 2025
pulisher
May 26, 2025

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie - insights.citeline.com

May 26, 2025
pulisher
May 25, 2025

CERE DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.

May 25, 2025
pulisher
May 24, 2025

AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer - MSN

May 24, 2025
pulisher
May 24, 2025

U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result - The Motley Fool

May 24, 2025
pulisher
May 23, 2025

Key Drivers Behind AbbVie’s (ABBV) Performance - Insider Monkey

May 23, 2025
pulisher
May 23, 2025

Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineABBV - marketscreener.com

May 23, 2025
pulisher
May 22, 2025

AbbVie (NYSE:ABBV) Faces Legal Scrutiny Over Merger With Cerevel - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient - Investing News Network

May 22, 2025
pulisher
May 22, 2025

AbbVie Secures Legal Victory Over Allergan Share Dispute - USA Herald

May 22, 2025
pulisher
May 22, 2025

Interleukin Inhibitors Market Detailed In New Research Report - openPR.com

May 22, 2025
pulisher
May 22, 2025

AbbVie (ABBV) has a Stable and Highly Profitable Business Model - Insider Monkey

May 22, 2025
pulisher
May 22, 2025

Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change - Pharma Voice

May 22, 2025
pulisher
May 22, 2025

Cerevel Therapeutics Holdings, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before June 3, 2025 to Discuss Your RightsABBV - marketscreener.com

May 22, 2025
pulisher
May 21, 2025

AbbVie Gets Victory In Allergan Shareholder Suit Upheld - Law360

May 21, 2025
pulisher
May 21, 2025

Court upholds dismissal of AbbVie-Allergan merger suit - Crain's Chicago Business

May 21, 2025
pulisher
May 21, 2025

AbbVie, Allergan Merger Suit Dismissal Upheld By Illinois Court - Bloomberg Law News

May 21, 2025
pulisher
May 21, 2025

Cancer Cachexia Market Detailed in New Research Report By 2032 | AbbVie Inc., Actimed Therapeutics - openPR.com

May 21, 2025
pulisher
May 21, 2025

Rheumatoid Arthritis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH - The Globe and Mail

May 21, 2025
pulisher
May 21, 2025

Plastic Surgery Market Fly Massive Growth in Years to Come: AbbVie, Johnson & Johnson Services, Sientra - openPR.com

May 21, 2025
pulisher
May 20, 2025

AbbVie Hits Last Generic-Orilissa Holdout With New Patent Suit - Bloomberg Law News

May 20, 2025
pulisher
May 20, 2025

AbbVie (ABBV) Soared on Favorable Tailwinds - MSN

May 20, 2025
pulisher
May 20, 2025

Ameriprise Financial Initiates AbbVie at Buy - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class ActionABBV - Morningstar

May 20, 2025
pulisher
May 20, 2025

Former AbbVie, Takeda omnichannel lead Dan Gandor joins Eversana Intouch - Medical Marketing and Media

May 20, 2025
pulisher
May 19, 2025

Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class ActionABBV - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie - Yahoo Finance

May 19, 2025
pulisher
May 17, 2025

Perion, Sea, KKR, Chimera, AbbVie: Trending by Analysts - TipRanks

May 17, 2025
pulisher
May 16, 2025

Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock” - MSN

May 16, 2025
pulisher
May 16, 2025

AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear - simplywall.st

May 16, 2025
pulisher
May 16, 2025

Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings - Yahoo Finance

May 16, 2025
pulisher
May 16, 2025

3 Stocks That Will Profit From Trump's Drug Price CutAbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN) - Benzinga

May 16, 2025
pulisher
May 16, 2025

Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm - TradingView

May 16, 2025
pulisher
May 15, 2025

7th Circ. Weighs AbbVie Whistleblower's Drug Marketing Suit - Law360

May 15, 2025
pulisher
May 15, 2025

AbbVie’s Solid Tumor Strategy Gets a Win With Accelerated FDA Approval in Lung Cancer - MedCity News

May 15, 2025

Abbvie Inc (ABBV) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general JNJ
$152.43
price down icon 0.54%
drug_manufacturers_general NVS
$111.87
price down icon 1.18%
drug_manufacturers_general NVO
$68.60
price down icon 2.61%
drug_manufacturers_general MRK
$76.17
price down icon 1.83%
drug_manufacturers_general GSK
$39.18
price down icon 0.66%
大文字化:     |  ボリューム (24 時間):